Social phobia

Summary

Social phobia (MONDO:0001247) is a disease and 309 clinical trials. Top therapeutic interventions include paroxetine, fluvoxamine, and cycloserine. A subtype of phobic disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 309

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	social phobia
Mondo ID	MONDO:0001247
EFO	EFO:1001917
MeSH	D000072861
DOID	DOID:11257
ICD-10-CM	F40.1
ICD-11	2062286624
NCIT	C34927
SNOMED CT	25501002
UMLS	C0031572
MedGen	19254
Is cancer (heuristic)	no

Also known as: social anxiety disorder

Disease family

This is a subtype of phobic disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by developmental or physiological process › psychiatric disorder › mental disorder › anxiety disorder › phobic disorder › social phobia

Related subtypes (2): agoraphobia, specific phobia

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

0 approved, 7 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Cycloserine	Phase 3 (in late-stage trials)
Fasedienol	Phase 3 (in late-stage trials)
Fluoxetine	Phase 3 (in late-stage trials)
Fluvoxamine	Phase 3 (in late-stage trials)
Paroxetine	Phase 3 (in late-stage trials)
Quetiapine	Phase 3 (in late-stage trials)
Sertraline	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Atomoxetine, Cannabidiol, Escitalopram, Fish Oil, Icosapent, Midomafetamine, Oxytocin, Tradipitant, Ziprasidone.

Clinical trials & evidence

Clinical trials

Clinical trials: 309.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	211
PHASE2	30
PHASE3	25
PHASE4	19
PHASE1	8
PHASE2/PHASE3	6
PHASE1/PHASE2	5
EARLY_PHASE1	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07192367	PHASE4	RECRUITING	Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder
NCT00177008	PHASE4	COMPLETED	Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety
NCT00182455	PHASE4	TERMINATED	Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)
NCT00208741	PHASE4	COMPLETED	Study To Evaluate The Effects Of Gabitril™ In Patients With Social Anxiety Disorder
NCT00231348	PHASE4	COMPLETED	Nefazodone in the Treatment of Social Phobia
NCT00246441	PHASE4	COMPLETED	Paroxetine for Comorbid Social Anxiety Disorder and Alcoholism
NCT00282828	PHASE4	COMPLETED	Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder
NCT00330174	PHASE4	COMPLETED	Acamprosate in Alcoholics With Comorbid Anxiety or Depression
NCT00347269	PHASE4	COMPLETED	Primary Care Intervention Strategy for Anxiety Disorders
NCT00407199	PHASE4	COMPLETED	The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment
NCT00633984	PHASE4	COMPLETED	D-Cycloserine Enhancement of Exposure in Social Phobia
NCT00902226	PHASE4	COMPLETED	Escitalopram in Patients With Social Anxiety Disorder
NCT01224067	PHASE4	COMPLETED	Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults
NCT01316302	PHASE4	COMPLETED	12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder
NCT02294305	PHASE4	UNKNOWN	Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder
NCT02790736	PHASE4	TERMINATED	Brief Intervention to Reduce Fear of Public Speaking
NCT03522844	PHASE4	COMPLETED	Treatments for Anxiety: Meditation and Escitalopram
NCT03785223	PHASE4	COMPLETED	A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
NCT05384483	PHASE4	COMPLETED	Cariprazine Versus Placebo for Social Anxiety Disorder
NCT06358651	PHASE3	ACTIVE_NOT_RECRUITING	Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3)
NCT06615557	PHASE3	ACTIVE_NOT_RECRUITING	Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)
NCT07221578	PHASE3	RECRUITING	Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT00000389	PHASE3	COMPLETED	Treatment for Anxiety in Children
NCT00043537	PHASE3	COMPLETED	Treatment of Childhood Social Phobia
NCT00052078	PHASE3	COMPLETED	Child and Adolescent Anxiety Disorders (CAMS)
NCT00074802	PHASE3	COMPLETED	Adding Cognitive Behavioral Therapy to Drug Treatment for Social Anxiety Disorder
NCT00215254	PHASE2/PHASE3	COMPLETED	Quetiapine in Social Anxiety Disorder
NCT00238719	PHASE3	COMPLETED	Study Evaluating Venlafaxine ER in Children and Adolescents With Social Anxiety Disorder
NCT00264654	PHASE3	COMPLETED	Long-term Study Of Paroxetine in Women and Men
NCT00302770	PHASE3	TERMINATED	Efficacy of Quetiapine in Generalised Social Anxiety Disorder
NCT00318669	PHASE3	COMPLETED	Social Anxiety Disorder Study Of Paroxetine
NCT00326430	PHASE2/PHASE3	COMPLETED	Residential Cognitive and Interpersonal Therapy for Social Phobia
NCT00515879	PHASE3	COMPLETED	Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia
NCT00564967	PHASE3	COMPLETED	A Comparison Between Internet Therapy and Group Therapy for Social Phobia - A Trial Using Cognitive Behavioural Therapy
NCT00619138	PHASE3	COMPLETED	Treatment of Social Phobia and Panic Disorder in Adults
NCT00773162	PHASE3	COMPLETED	Flushing in Social Anxiety Disorder on Seroquel
NCT00958880	PHASE3	COMPLETED	Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
NCT01178385	PHASE2/PHASE3	COMPLETED	Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders
NCT01388231	PHASE2/PHASE3	UNKNOWN	Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice
NCT01416805	PHASE3	COMPLETED	Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
PAROXETINE	4	14
FLUVOXAMINE	4	6
CYCLOSERINE	4	5
CARIPRAZINE	4	3
FLUOXETINE	4	3
NEFAZODONE	4	3
PROPRANOLOL	4	3
QUETIAPINE	4	3
VENLAFAXINE	4	3
VILAZODONE	4	3
ZIPRASIDONE	4	3
CANNABIDIOL	4	2
SERTRALINE	4	2
TIAGABINE	4	2
ACAMPROSATE	4	1
ALPRAZOLAM	4	1
ARIPIPRAZOLE	4	1
CLONAZEPAM	4	1
DESVENLAFAXINE SUCCINATE	4	1
ESCITALOPRAM	4	1
METHYLPHENIDATE	4	1
RILUZOLE	4	1
SCOPOLAMINE	4	1
TOPIRAMATE	4	1
VORTIOXETINE	4	1
FASEDIENOL	3	2
CASOPITANT	3	1
CENTANAFADINE	3	1
MIDOMAFETAMINE	3	1
TRADIPITANT	3	1